Desarrollo de una solución integrada para pacientes con dolor crónico portadores de neuroestimulador en tiempos del COVID-19: una aplicación para móvil con centro de soporte / Development of an integrated solution for patients with neurostimulator for chronic pain in times of COVID-19: A mobile application with a support center

Introducción El dolor crónico es una de las afecciones más prevalentes en el mundo. El tratamiento con neuroestimuladores se realiza en los casos más extremos tras una cuidadosa selección, y demanda una gran inversión de recursos en su seguimiento. En estos momentos de pandemia por la COVID-19, presentamos una solución integrada para el seguimiento de estos de pacientes, que incluye el desarrollo de una aplicación para dispositivos móviles y un centro de soporte para seguimiento remoto (CSSR). Material y metodología El proyecto se ha desarrollado basándose en evidencia científica en las siguientes fases: 1) Aprobación de la idea en sesión clínica multidisciplinar de implantes para dolor crónico, 2) Formación de un grupo de expertos, 3) Adaptación del protocolo para el seguimiento de los pacientes con dolor crónico a las características del entorno de un smartphone, 4) Adaptación de la plataforma tecnológica al protocolo clínico (entorno tecnológico y flujo de trabajo entre el hospital y el CSSR) y 5) Evaluación de la calidad mediante encuesta (cuantitativa y cualitativa) con una pequeña muestra de pacientes. Resultados La aplicación de paciente se evaluó solicitando opiniones de los usuarios sobre el diseño y la utilidad de la misma entre los primeros pacientes implantados que la usaron. Se realizaron algunos ajustes menores en relación con el material para descargar, y sobre el texto y el color de la pantalla. Conclusiones El proceso de creación de una solución integrada debe estar basado en principios científicos y acorde con los protocolos establecidos. Un centro de soporte permite asegurar una mayor adherencia al seguimiento y una mejor atención a los pacientes (AU)

Introduction Chronic pain is one of the most prevalent pathologies in the world. Treatment with neurostimulators is carried out in the most extreme cases and requires a large investment of resources. In these times of COVID-19 pandemic, we present a comprehensive solution for monitoring this kind of patient, this solution includes the development of a mobile application and a support center for remote monitoring (SCRM). MMaterial and methodology The project was developed according to the scientific evidence in the following phases: (1) approval in a multidisciplinary clinical committee of implants for chronic pain, (2) setting up a group of experts, (3) protocol adaptation for the follow-up of patients with chronic pain to the Smartphone environment, (4) technology platform adaptation to the clinical protocol (technological environment and workflow between the hospital and the SCRM), and (5) quality evaluation by survey (quantitative and qualitative) of a small series of patients. Results The application was evaluated by asking for user opinions about design and usefulness with the first implanted patients. Some minor adjustments were made concerning downloadable material and screen color and text. Conclusions Developing a comprehensive solution should be based on scientific principles and in accordance with established protocols. A support center ensures greater adherence for follow-up and better patient care (AU)

[Development of an integrated solution for patients with neurostimulator for chronic pain in times of COVID-19: A mobile application with a support center]. / Desarrollo de una solución integrada para pacientes con dolor crónico portadores de neuroestimulador en tiempos del COVID-19: una aplicación para móvil con centro de soporte.

Introduction: Chronic pain is one of the most prevalent pathologies in the world. Treatment with neurostimulators is carried out in the most extreme cases and requires a large investment of resources. In these times of COVID-19 pandemic, we present a comprehensive solution for monitoring this kind of patient, this solution includes the development of a mobile application and a support center for remote monitoring (SCRM). MMaterial and methodology: The project was developed according to the scientific evidence in the following phases: (1) approval in a multidisciplinary clinical committee of implants for chronic pain, (2) setting up a group of experts, (3) protocol adaptation for the follow-up of patients with chronic pain to the Smartphone environment, (4) technology platform adaptation to the clinical protocol (technological environment and workflow between the hospital and the SCRM), and (5) quality evaluation by survey (quantitative and qualitative) of a small series of patients. Results: The application was evaluated by asking for user opinions about design and usefulness with the first implanted patients. Some minor adjustments were made concerning downloadable material and screen color and text. Conclusions: Developing a comprehensive solution should be based on scientific principles and in accordance with established protocols. A support center ensures greater adherence for follow-up and better patient care.

Development of an integrated solution for patients with neurostimulator for chronic pain in times of COVID-19: A mobile application with a support center.

INTRODUCTION: Chronic pain is one of the most prevalent pathologies in the world. Treatment with neurostimulators is carried out in the most extreme cases and requires a large investment of resources. In these times of the COVID19 pandemic, we present a comprehensive solution for monitoring this kind of patient, this solution includes the development of a mobile application and a support center for remote monitoring (SCRM). MATERIAL AND METHODOLOGY: The project was developed according to the scientific evidence in the following phases: (1) Approval in a multidisciplinary clinical committee of implants for chronic pain, (2) Setting up a group of experts, (3) Protocol adaptation for the follow-up of patients with chronic pain to the Smartphone environment, (4) Technology platform adaptation to the clinical protocol (technological environment and workflow between the hospital and the SCRM), and (5) Quality evaluation by survey (quantitative and qualitative) of a small series of patients. RESULTS: The application was evaluated by asking for user opinions about design and usefulness with the first implanted patients. Some minor adjustments were made concerning downloadable material and screen color and text. CONCLUSIONS: Developing a comprehensive solution should be based on scientific principles and in accordance with established protocols. A support center ensures greater adherence for follow-up and better patient care.

Hidrocefalia crónica del adulto: diagnóstico, tratamiento y evolución. Estudio prospectivo / Adult chronic idiopathic hydrocephalus-diagnosis, treatment and evolution. Prospective study

INTRODUCCIÓN: Actualmente la hidrocefalia crónica del adulto (HCA) se presenta como una patología de diagnóstico controvertido en la que se han usado múltiples técnicas diagnósticas y terapéuticas con diferentes grados de éxito postoperatorio. El objetivo de nuestro estudio es evaluar una serie de pacientes diagnosticados de HCA idiopática y tratados con derivación de LCR en nuestro centro entre los años 2006 y 2009 mediante escalas clínicas y controles radiológicos pre y postoperatoriamente. MATERIAL Y MÉTODOS: Se analizan prospectivamente 40 pacientes. El diagnóstico de HCA idiopática se hizo cuando el paciente cumplía 3 tipos de criterios: a) clínicos, b) radiológicos (Evans > 0,3) y c) hidrodinámicos (test de infusión de Katzman con Rout [mmHg/ml/min] > 12) o monitorización de la PIC patológica (ondas B en más del 20% del registro nocturno). Se colocó una DVP de baja presión GAV 5/35 en todos los casos. Se realizaron revisiones clínicas a los 3, 6 y 12 meses y radiológicas a los 6 meses de la intervención, así como encuesta de satisfacción a los 12 meses. Se valoró la mejoría clínica del paciente mediante las escalas de puntuación NPH, RANKIN modificado y PFEIFFER modificado. RESULTADOS: El estudio de los factores de riesgo (edad, sexo, fumador, bebedor, HTA, DM, dislipidemia) no estableció relaciones estadísticamente significativas. Se evidenció mejoría global estadísticamente significativa (p < 0,01) en los test de Rankin y NPH a los 3, 6 y 12 meses, siendo las cifras: NPH 73, 74 y 64%, y RANKIN 54, 72 y 56% de mejoría, respectivamente. En el PFEIFFER solo se evidenció mejoría significativa a los 12 meses. Dichas mejorías se clasificaron en niveles (elevada, moderada, leve y no mejoría). El índice de Evans inicial medio fue 0,385, postoperatorio 0,3675. Solo ocurrió una infección del sistema valvular (2%), sin secuelas. La mortalidad y la morbilidad relacionadas con el procedimiento fueron del 0%. CONCLUSIÓN: Una adecuada selección de los pacientes con criterios clínicos, radiológicos, hidrodinámicos y de monitorización de la PIC permite la obtención de buenos resultados con bajo índice de complicaciones

INTRODUCTION: At present, chronic hydrocephalus or normal pressure hydrocephalus (NPH) has a controversial diagnosis in which multiple diagnostic and therapeutic techniques have been used with variable degrees of postoperative success. The aim of our study is to evaluate a number of patients diagnosed with adult chronic idiopathic hydrocephalus who were treated with a CSF shunt at our centre between 2006 and 2009 through clinical scales and radiological controls pre- and postoperatively. MATERIAL AND METHODS: We prospectively analysed 40 patients. The diagnosis of idiopathic NPH was established when patients met 3 criteria: (I) clinical; (II) radiological (Evans >0.3), and (III) hydrodynamic (Katzman infusion test with Rout > 12) or pathological ICP monitoring (B waves in over 20% of a nocturnal registration). We used a low-pressure DVP 5/35 GAV in all cases. Clinical assessments were conducted at 3, 6 and 12 months and radiological assessments at 6 months postoperatively. The clinical improvement of patients was assessed with the NPH, modified RANKIN and modified PFEIFFER rating scales. RESULTS: The study of risk factors (age, gender, smoking, drinking, arterial hypertension, diabetes mellitus, dyslipidemia) did not establish statistically significant relationships. A statistically significant improvement was observed (P<.01) in the NPH and RANKIN tests at 3, 6 and 12 months. Clinical improvement values obtained were: NPH 73%, 74% and 64%, and RANKIN 54%, 72% and 56%, respectively. The PFEIFFER scale only showed a significant improvement at 12 months. These improvements were classified into various levels (high, moderate, mild and no improvement). The initial mean Evans index was 0.385, and 0.3675 postoperatively. There was only one infection of the valvular system (2%) without further complications. Morbidity and mortality related to the procedure were 0%. CONCLUSION: An appropriate selection of patients through clinical, radiological, hydrodynamic and ICP monitoring criteria enables us to obtain good results and a low complication rate

[Adult chronic idiopathic hydrocephalus-diagnosis, treatment and evolution. Prospective study]. / Hidrocefalia crónica del adulto: diagnóstico, tratamiento y evolución. Estudio prospectivo.

INTRODUCTION: At present, chronic hydrocephalus or normal pressure hydrocephalus (NPH) has a controversial diagnosis in which multiple diagnostic and therapeutic techniques have been used with variable degrees of postoperative success. The aim of our study is to evaluate a number of patients diagnosed with adult chronic idiopathic hydrocephalus who were treated with a CSF shunt at our centre between 2006 and 2009 through clinical scales and radiological controls pre- and postoperatively. MATERIAL AND METHODS: We prospectively analysed 40 patients. The diagnosis of idiopathic NPH was established when patients met 3 criteria: (i)clinical; (ii)radiological (Evans >0.3), and (iii)hydrodynamic (Katzman infusion test with Rout >12) or pathological ICP monitoring (B waves in over 20% of a nocturnal registration). We used a low-pressure DVP 5/35 GAV in all cases. Clinical assessments were conducted at 3, 6 and 12 months and radiological assessments at 6 months postoperatively. The clinical improvement of patients was assessed with the NPH, modified RANKIN and modified PFEIFFER rating scales. RESULTS: The study of risk factors (age, gender, smoking, drinking, arterial hypertension, diabetes mellitus, dyslipidemia) did not establish statistically significant relationships. A statistically significant improvement was observed (P<.01) in the NPH and RANKIN tests at 3, 6 and 12 months. Clinical improvement values obtained were: NPH 73%, 74% and 64%, and RANKIN 54%, 72% and 56%, respectively. The PFEIFFER scale only showed a significant improvement at 12 months. These improvements were classified into various levels (high, moderate, mild and no improvement). The initial mean Evans index was 0.385, and 0.3675 postoperatively. There was only one infection of the valvular system (2%) without further complications. Morbidity and mortality related to the procedure were 0%. CONCLUSION: An appropriate selection of patients through clinical, radiological, hydrodynamic and ICP monitoring criteria enables us to obtain good results and a low complication rate.